Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simeone, A.-M.
Right arrow Articles by Tari, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simeone, A.-M.
Right arrow Articles by Tari, A. M.
Vol. 1, 1009-1017, October 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

A Novel Mechanism by Which N-(4-hydroxyphenyl)retinamide Inhibits Breast Cancer Cell Growth: The Production of Nitric Oxide

Ann-Marie Simeone, Suhendan Ekmekcioglu, Lyle D. Broemeling, Elizabeth A. Grimm and Ana M. Tari1

Department of Bioimmunotherapy, Sections of Immunobiology and Drug Carriers [A-M. S., A. M. T.] and Immunotherapy [S. E., E. A. G.] and Department of Biostatistics [L. D. B.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

N-(4-Hydroxyphenyl)retinamide (4-HPR) induces apoptosis in breast cancer cells; however, the molecular basis by which 4-HPR induces apoptosis is not well understood. In breast cancer cells, nitric oxide (NO) is predominantly an apoptotic inducer. Apoptotic agents, such as phorbol ester, tumor necrosis factor-{alpha}, and peptide hormones, have been shown to increase NO production in breast cancer cells. Therefore, we hypothesized that the production of NO is vital for 4-HPR to induce apoptosis in breast cancer cells. We found that 4-HPR induced NO production in a dose-dependent manner in all of the breast cancer cell lines tested. The degree of growth inhibition and apoptotic induction by 4-HPR was directly correlated with the amount of NO produced. To prove that NO is essential for 4-HPR to induce apoptosis, breast cancer cells were coincubated with a competitive NO synthase (NOS) inhibitor, NG-monomethyl-L-arginine (L-NMMA), and 4-HPR. L-NMMA prevented 4-HPR from inducing inhibitory effects, indicating that NO is crucial for 4-HPR to induce its apoptotic effects in breast cancer cells. IFNs and tamoxifen (TAM) have been shown to potentiate 4-HPR effects in breast cancer cells. Both IFN-{gamma} and TAM enhanced the ability of 4-HPR to induce NO production in breast cancer cells, which was correlated with increased apoptosis. Alone, 4-HPR increased expression of both inducible NOS (NOSII) and endothelial NOS (NOSIII). When combined with 4-HPR, IFN-{gamma} and TAM enhanced NOSII expression. Thus, we have identified a novel mechanism by which 4-HPR induces apoptosis in breast cancer cells, i.e., by increasing NOS expression to induce NO production.




This article has been cited by other articles:


Home page
Cancer Res.Home page
H. Kadara, E. Tahara, H.-J. Kim, D. Lotan, J. Myers, and R. Lotan
Involvement of Rac in Fenretinide-Induced Apoptosis
Cancer Res., June 1, 2008; 68(11): 4416 - 4423.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-H. Hung, Y.-S. Lu, Y.-C. Wang, Y.-H. Ma, D.-S. Wang, S. K. Kulp, N. Muthusamy, J. C. Byrd, A.-L. Cheng, and C.-S. Chen
FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C {delta} Signaling
Cancer Res., February 15, 2008; 68(4): 1204 - 1212.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A.-M. Simeone, S. Colella, R. Krahe, M. M. Johnson, E. Mora, and A. M. Tari
N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells
Carcinogenesis, March 1, 2006; 27(3): 568 - 577.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A.-M. Simeone, Y.-J. Li, L. D. Broemeling, M. M. Johnson, M. Tuna, and A. M. Tari
Cyclooxygenase-2 Is Essential for HER2/neu to Suppress N- (4-Hydroxyphenyl)retinamide Apoptotic Effects in Breast Cancer Cells
Cancer Res., February 15, 2004; 64(4): 1224 - 1228.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Crowell, V. E. Steele, C. C. Sigman, and J. R. Fay
Is Inducible Nitric Oxide Synthase a Target for Chemoprevention?
Mol. Cancer Ther., August 1, 2003; 2(8): 815 - 823.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.